NEW YORK (Reuters Health) – Physicians should monitor serum testosterone levels during androgen-deprivation therapy (ADT) in men with prostate cancer, according to an April 16th online report in…
NEW YORK (Reuters Health) – Using recombinant tissue plasminogen activator (rtPA) within existing licensing limits is fully justified by available data – but there’s not enough data to…
NEW YORK (Reuters Health) – The angiotensin II receptor blocker olmesartan medoxomil (Benicar) significantly reduces blood pressure in children with primary or secondary hypertension, according to an international…
NEW YORK (Reuters Health) – Intravenous magnesium sulfate (MgSO4) does not benefit patients with acute aneurysmal subarachnoid hemorrhage, according to results of a phase III trial. In the…
NEW YORK (Reuters Health) – Although promethazine and metoclopramide have similar antiemetic effects in hyperemesis gravidarum, metoclopramide has fewer side effects, according to a study published online April…
NEW YORK (Reuters Health) – The nonselective beta-blocker carvedilol and the beta-1-selective beta-blockers metoprolol succinate and bisoprolol have significantly different treatment effects in patients with chronic heart failure…
NEW YORK (Reuters Health) – Positron emission tomography (PET) of the liver is extremely unreliable in patients who’ve just had chemotherapy for colorectal cancer metastases, because the false-negative…
NEW YORK (Reuters Health) – Clopidogrel reloading does not benefit patients undergoing percutaneous coronary intervention (PCI) who are already on chronic clopidogrel therapy, Italian researchers reported online April…
NEW YORK (Reuters Health) – In older patients with normal lipids but high C-reactive protein, primary prevention therapy with rosuvastatin (Crestor) does not lower mortality, but it does…
NEW YORK (Reuters Health) – Anemia increases the risk of bleeding and death after percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), a new study shows.…
